Natural Products and Traditional Herbal Medicines as Managerial Therapies to Combat Rheumatoid Arthritis

Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: from synovium biology to cell-based therapy. Cytotherapy. 2022;24(4):365–75.

Article  CAS  PubMed  Google Scholar 

Rheumatoid arthritis. 2023. https://www.who.int/news-room/fact-sheets/detail/rheumatoid-arthritis.

Gupta BM, Gupta R, Kumar A, Bansal M. Rheumatoid arthritis research in India: a scientometric assessment of publications during 2007–2016.  SF J Orthopedic Rheumatol 2018.

Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(3):279.

Article  PubMed  PubMed Central  Google Scholar 

McGraw WT, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun. 1999;67(7):3248–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin Y-J, Anzaghe M, Schülke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020;9(4):880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson AS, Loeser RF. Why is osteoarthritis an age-related disease?, Best practice & research. Clin Rheumatol. 2010;24(1):15–26.

Google Scholar 

Littlejohn EA, Monrad SU. Early diagnosis and treatment of rheumatoid arthritis. Primary care: Clinics in office practice. 2018;45(2):237–55.

Article  PubMed  Google Scholar 

Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone res. 2018;6(1):15.

Article  PubMed  PubMed Central  Google Scholar 

Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med. 2015;53(2):128–32.

CAS  PubMed  Google Scholar 

Charleson K. Types of rheumatoid arthritis. 2023. https://www.verywellhealth.com/types-of-rheumatoid-arthritis-5093089#citation-7. Accessed 11/11/2023 2023.

Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.

Article  PubMed  Google Scholar 

Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. The Lancet. 2017;389(10086):2338–48.

Article  Google Scholar 

Watanabe R, Okano T, Gon T, Yoshida N, Fukumoto K, Yamada S, Hashimoto M. Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems. Front Med (Lausanne). 2022;9:1049875.

Article  PubMed  Google Scholar 

Wang Y, Chen S, Du K, Liang C, Wang S, Boadi EO, Li J, Pang X, He J. Chang Y-x, Traditional herbal medicine: therapeutic potential in rheumatoid arthritis. J Ethnopharmacol. 2021;279: 114368.

Article  CAS  PubMed  Google Scholar 

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a register study. Rheumatology. 2016;55(10):1803–11.

Article  PubMed  Google Scholar 

Papadopoulou D, Roumelioti F, Tzaferis C, Chouvardas P, Pedersen A-K, Charalampous F, Christodoulou-Vafeiadou E, Ntari L, Karagianni N, Denis MC. Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis. JCI insight. 2023;8:9.

Article  Google Scholar 

Benjamin O, Goyal A, Lappin SL. Disease-modifying antirheumatic drugs (DMARD). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

Choi J, Fenando A. Sulfasalazine. StatPearls, StatPearls Publishing; 2022.

Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). StatPearls, StatPearls Publishing; 2023.

Waller DG, Sampson AP. 30 - Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis, in: D.G. Waller, A.P. Sampson (Eds.). Medical Pharmacology and Therapeutics (Fifth Edition). Elsevier; 2018. pp. 373–383.

Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA. Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial. Arthritis Rheumatol. 2020;72(9):1435–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu H, Yan S, Chen J, Luo X, Li P, Jia X, Dai X, Wang C, Huang Q, Liu L. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells. Joint Bone Spine. 2016;83(5):525–32.

Article  CAS  PubMed  Google Scholar 

Conaghan PG, Nowak M, Du S, Luo Y, Landis J, Pachai C, Fura A, Catlett IM, Grasela DM, Østergaard M. Evaluation of BMS-986142, a reversible Bruton’s tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet Rheumatol. 2023;5(5):e263–73.

Article  CAS  PubMed  Google Scholar 

Tanaka Y, Genovese MC, Matsushima H, Long-term safety, efficacy, and patient-centered outcomes of filgotinib in the treatment of rheumatoid arthritis: current perspectives, patient preference and adherence 2023;2499–2516.

Peterfy CG, Strand V, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa JV, Shaw T, Li Y. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. Rheumatology. 2022;61(8):3246–56.

Article  CAS  PubMed  Google Scholar 

Daien C, Krogulec M, Gineste P, Steens J-M, Du Roure LD, Biguenet S, Scherrer D, Santo J, Ehrlich H, Durez P. Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study. Ann Rheum Dis. 2022;81(8):1076–84.

Article  CAS  PubMed  Google Scholar 

Yoon S-B, Hong H, Lim H-J, Choi JH, Choi YP, Seo SW, Lee HW, Chae CH, Park W-K, Kim HY. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway. Acta Pharmaceutica Sinica B. 2023;13(3):1093–109.

Article  CAS  PubMed  Google Scholar 

Li J, Li M, Wu D, Zhou J. Leung S-o, Zhang F, SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Rheumatology. 2022;61(5):1841–8.

Article  CAS  PubMed  Google Scholar 

Gordon D, Kivitz A, Singhal A, Burt D, Bangs MC, Huff EE, Hope HR, Monahan JB. Selective inhibition of the MK2 pathway: data from a phase IIa randomized clinical trial in rheumatoid arthritis. ACR Open Rheumatology. 2023;5(2):63–70.

Article  PubMed  PubMed Central  Google Scholar 

Robak E, Robak T. Bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J Clin Med. 2022;11(10):2807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montalban X, Wallace D, Genovese MC, et al. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. J Neurol Neurosurg Psychiatry. 2023;94(1):1–9.

Article  PubMed  Google Scholar 

Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis. Clin Rheumatol. 2023;42(6):1503–20.

Article  PubMed  PubMed Central  Google Scholar 

Takeuchi T, Chino Y, Kawanishi M, Nakanishi M, Watase H, Mano Y, Sato Y, Uchida S, Tanaka Y. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials. Arthritis Res Ther. 2023;25(1):60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Davies J, Goode C. Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023;82(12):1527–37.

Article  CAS  PubMed  Google Scholar 

Muralidharan S, Njenga M, Garron T, Bondensgaard K, Paolini JF. Preclinical immunopharmacologic assessment of KPL-404, a novel, humanized, non-depleting antagonistic anti-CD40 monoclonal antibody. J Pharmacol Exp Ther. 2022;381(1):12–21.

Article  CAS  PubMed  Google Scholar 

Buttgereit F, Aelion J, Rojkovich B, Zubrzycka-Sienkiewicz A, Chen S, Yang Y, Arikan D, D’Cunha R, Pang Y, Kupper H. Efficacy and safety of ABBV-3373, a novel anti–tumor necrosis factor glucocorticoid receptor modulator antibody–drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase IIa trial. Arthritis & Rheumatology. 2023;75(6):879–89.

Article  CAS  Google Scholar 

Deligiannidou G-E, Gougoula V, Bezirtzoglou E, Kontogiorgis C, Constantinides TK. The role of natural products in rheumatoid arthritis: current knowledge of basic in vitro and in vivo research. Antioxidants. 2021;10(4):599.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Edilova MI, Akram A, Abdul-Sater AA. Innate immunity drives pathogenesis of rheumatoid arthritis. biomed j. 2021;44(2):172–82.

Article  CAS  PubMed  Google Scholar 

Laurindo LF, de Maio MC, Barbalho SM, Guiguer EL, Araújo AC, de Alvares GR, Flato UAP, Júnior EB, Detregiachi CRP, dos Santos Haber JF. Organokines in rheumatoid arthritis: a critical review. Int J Mol Sci. 2022;23(11):6193.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Veselinovic M, Barudzic N, Vuletic M, Zivkovic V, Tomic-Lucic A, Djuric D, Jakovljevic V. Oxidative stress in rheumatoid arthritis patients: relationship to diseases activity. Mol Cell Biochem. 2014;391:225–32.

Article  CAS  PubMed  Google Scholar

Comments (0)

No login
gif
Back To Top